FDA has accepts Genentech’s BLA for a subcutaneous formulation of rituximab in blood cancer indications

HALOZYME THERAPEUTICS INC. said FDA has accepted Genentech’s Biologics License Application for a subcutaneous formulation of rituximab in multiple blood cancer indications. This is a co-formulation with Halozyme’s proprietary recombinant human hyaluronidase enzyme (ENHANZE platform), approved and marketed under the MabThera SC brand in countries outside the U.S. Halozyme Therapeutics is a biotechnology company focused...